Effect of Compatibility of Wujiwan on Pharmacokinetics and Tissue Distribution of Representative Components
10.13422/j.cnki.syfjx.20231169
- VernacularTitle:戊己丸配伍对代表成分体内药代动力学和组织分布的影响
- Author:
Yu DONG
1
;
Ying CHEN
2
;
Zipeng GONG
3
;
Qing YANG
2
;
Xiaogang WENG
2
;
Yajie WANG
2
;
Xiaoxin ZHU
2
;
Chenhao ZHANG
4
Author Information
1. Guang′anmen Hospital，China Academy of Chinese Medical Sciences，Beijing 100053，China
2. Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences，Beijing 100700，China
3. Guizhou Provincial Key Laboratory of Pharmaceutics，Guizhou Medical University，Guizhou 550004，China
4. Wangjing Hospital，China Academy of Chinese Medical Sciences，Beijing 100102，China
- Publication Type:Journal Article
- Keywords:
Wujiwan;
compatibility of formulas;
pharmacokinetics;
tissue distribution;
Coptidis Rhizoma;
Euodiae Fructus;
Paeoniae Radix Alba
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2024;30(3):105-113
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo study the plasma pharmacokinetics and tissue distribution of five representative components in Wujiwan， and to illustrate the difference of metabolism and tissue distribution before and after compatibility. MethodHealthy male SD rats were divided into four groups， including Wujiwan group（A group， 62.96 g·L-1）， Coptidis Rhizoma group（B group， 38.4 g·L-1）， processed Euodiae Fructus group（C group， 5.88 g·L-1） and fried Paeoniae Radix Alba group（D group， 18.68 g·L-1）， with 65 rats in each group， and were administered the drugs according to the clinical dose of decoction pieces converted into the dose of the extracts. Then plasma， liver， small intestine and brain were taken at pharmacokinetic set time in each group after administration. Ultra-high performance liquid chromatography-triple quadrupole tandem mass spectrometry was developed for the quantitative analysis of five representative components［berberine（Ber）， palmatine（Pal）， evodiamine（Evo）， rutecarpine（Rut） and paeoniflorin（Pae）］ in Wujiwan， their concentrations in plasma， liver， small intestine and brain were detected at different time， plasma samples were processed by protein precipitation， and tissue samples were pretreated by protein precipitation plus liquid-liquid extraction. Non-atrioventricular model was used to calculate the pharmacokinetic parameters of each component， and the parameters of each group were compared. ResultPharmacokinetic results of A group showed that area under the curve（AUC0-t） of the five representative components were ranked as follows：Ber and Pal were small intestine>liver>blood， Evo and Rut were liver>small intestine>plasma， Pae was small intestine>plasma， which was not detected in the liver， no other components were detected in brain except for Ber. In comparison with plasma and other tissues， peak concentration（Cmax） of Ber， Pal， Evo， and Rut were the highest and time to peak（tmax） were the lowest in the liver of A group. In plasma， the AUC0-t and Cmax of Evo and Rut were increased in A group compared with C group， tmax of Pea was elevated and its Cmax was decreased in A group compared with D group. In the liver， compared with B-D groups， Cmax values of 5 representative components except Pae were elevated， AUC0-t of Pae was decreased and AUC0-t of Evo and Rut were increased in the A group. In the small intestine， half-life（t1/2） of each representative components in A group was elevated and tmax was decreased， and Cmax of each representative ingredient except Pal was decreased， AUC0-t values of Ber and Pal were increased， whereas the AUC0-t values of Evo and Rut were decreased. ConclusionThe small intestine， as the effector organ， is the most distributed， followed by the liver. The pharmacokinetic parameters of the representative components in Wujiwan are changed before and after compatibility， which is more favorable to the exertion of its pharmacodynamic effects.
